[1] THOMSEN H S.Guidelines for contrast media from the European Society of Urogenital Radiology[J].AJR Am J Roentgenol,2003,181(6):1463-1471.
[2] KITAJIMA K,MAEDA T,WATANABE S,et al.Recent issues in contrast-induced nephropathy[J].Int J Urol,2011,18(10):686-690.
[3] NASH K,HAFEEZ A,HOU S.Hospital-acquired renal insufficiency[J].Am J Kidney Dis,2002,39(5):930-936.
[4] BARTHOLOMEW B A,HARJAI K J,DUKKIPATI S,et al.Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification[J].Am J Cardiol,2004,93(12):1515-1519.
[5] LEVY E M,VISCOLI C M,HORWITZ R I.The effect of acute renal failure on mortality.A cohort analysis[J].JAMA,1996,275(19):1489-1494.
[6] TUMLIN J,STACUL F,ADAM A,et al.Pathophysiology of contrast-induced nephropathy[J].Am J Cardiol,2006,98(6):14-20.
[7] ADAM A.Pathophysiology of contrast-induced nephropathy[J].Int J Cardiol,2012,158(2):186-192.
[8] GUASTONI C,DE S S.Pathophysiology of contrast-induced nephropathy[J].G Ital Cardiol,2009,10(2):73-78.
[9] MEHRAN R,AYMONG E D,NIKOLSKY E,et al.A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention:development and initial validation[J].J Am Coll Cardiol,2004,44(7):1393-1399.
[10] HO Y F,HSIEH K L,KUNG F L,et al.Nephrotoxic polypharmacy and risk of contrast medium-induced nephropathy in hospitalized patients undergoing contrast-enhanced CT[J].AJR Am J Roentgenol,2015,205(4):703-708.
[11] LUCHI W M,SHIMIZU M H,CANALE D,et al.Vitamin D deficiency is a potential risk factor for contrast-induced nephropathy[J].Am J Physiol Regul Integr Comp Physiol,2015,309(3):215-222.
[12] SAHIN I,GUNGOR B,CAN M M,et al.Lower blood vitamin d levels are associated with an increased incidence of contrast-induced nephropathy in patients undergoing coronary angiography[J].Can J Cardiol,2014,30(4):428-433.
[13] SERGIO R R,EMAD A A,RAYMUNDO O S,et al.Dosing of iodinated contrast volume:a new simple algorithm to stratify the risk of contrast-induced nephropathy in patients with acute coronary syndrome[J].Catheter Cardiovasc Interv,2013,82(6):888-897.
[14] WANG Y C,TANG A,CHANG D,et al.Long-term adverse effects of low-osmolar compared with iso-osmolar contrast media after coronary angiography[J].Am J Cardiol,2016,118(7):985-990.
[15] VANOMMESLAEGHE F,DE M E,VAN D B C,et al.Selecting a strategy for prevention of contrast-induced nephropathy in clinical practice:an evaluation of different clinical practice guidelines using the AGREE tool[J].Nephrol Dial Transplant,2015,30(8):1300-1306.
[16] SUBRAMANIAM R M,SUAREZ-CUERVO C,WILSON R F,et al.Effectiveness of prevention strategies for contrast-induced nephropathy:a systematic review and meta-analysis[J].Ann Intern Med,2016,164(6):406-416.
[17] KOC F,OZDEMIR K,KAYA M G,et al.Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy:CASIS-A multicenter prospective controlled trial[J].Int J Cardiol,2010,155(3):418-423.
[18] JAFFERY Z,VERMA A,WHITE C J,et al.A randomized trial of intravenous n-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes[J].Catheter Cardiovasc Interv,2012,79(6):921-926.
[19] HAN Y,ZHU G,HAN L,et al.Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease[J].J Am Coll Cardiol,2014,63(1):62-70.
[20] JO S H,HAHN J Y,LEE S Y,et al.High-dose atorvastatin for preventing contrast-induced nephropathy in primary percutaneous coronary intervention[J].J Cardiovasc Med,2014,16(3):213-219.
[21] SPARGIAS K,ALEXOPOULOS E,KYRZOPOULOS S,et al.Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention[J].Circulation,2004,110(120):1793-1799.
[22] ZHOU L,CHEN H.Prevention of contrast-induced nephropathy with ascorbic acid[J].Intern Med,2012,51:531-535.
[23] MALHIS M,ALBITAR S,ALDEEN Z K.The role of theophylline in prevention of radiocontrast media-induced nephropathy[J].Saudi J Kidney Dis Transpl,2010,21(2):276-283.
[24] MATEJKA J,VARVAROVSKY I,VOJTISEK P,et al.Prevention of contrast-induced acute kidney injury by theophylline in elderly patients with chronic kidney disease[J].Heart Vessels,2010,25(6):536-542.
[25] STONE G W,MCCULLOUGH P A,TUMLIN J A,et al.Fenoldopam mesylate for the prevention of contrast-induced nephropathy:a randomized controlled trial[J].JAMA,2004,290(17):2284-2291.
[26] NAEEM M,MCENTEGGART G E,MURPHY T P,et al.Fenoldopam for the prevention of contrast-induced nephropathy (CIN)-do we need more trials? A meta-analysis[J].Clin Imaging,2015,39(5):759-764.
[27] KOZA Y.The effects of chronic usage of enzyme inhibitors and angiotensin receptor blockers on contrast-induced nephropathy in low-risk patients[J].Anadolu Kardiyol Derg,2013,13(3):245-250.
[28] BAINEY K R,RAHIM S,ETHERINGTON K,et al.Effects of withdrawing versus continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization:results from the captain trial[J].Am Heart J,2015,170(1):110-116.
[29] ZHAO K,LI Y,ZHANG H.Role of Dongchongxiacao (Cordyceps) in prevention of contrast-induced nephropathy in patients with stable angina pectoris[J].中医杂志(英文版),2013,33(3):283-286.
[30] MARENZI G,LAURI G,CAMPODONICO J,et al.Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients[J].Am J Med,2006,119(2):155-162.
[31] CHOI M J,YOON J W,HAN S J,et al.The prevention of contrast-induced nephropathy by simultaneous hemofiltration during coronary angiographic procedures:a comparison with periprocedural hemofiltration[J].Int J Cardiol,2014,176(3):941-945. |
